Formulation and evaluation of a testosterone transdermal spray

Journal of Pharmaceutical Sciences

Volumn 95, Issue 8, 2006, Pages 1693-1702

  Leichtnam, Marie Laure ^a,b   Rolland, Hervé ^b   Wüthrich, Patrick ^b   Guy, Richard H ^a,c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c University of Bath   (United Kingdom)

Author keywords

Aerosols; Formulation; Passive diffusion; Skin; Transdermal drug delivery; Transport

Indexed keywords

ALCOHOL; DRUG VEHICLE; PROPYLENE GLYCOL; TESTOSTERONE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG SCREENING; NONHUMAN; RAT; SKIN PERMEABILITY;

EID: 33747182858     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20641     Document Type: Review

References (30)

1. Chien YW. 1987. Advances in transdermal systemic medication. In: Chien YW, editor. Transdermal controlled systemic medications. New York: Marcel Dekker. pp 1-22.
2. Beckett AH. 1982. Possibilities and limitations of transdermal absorption. In: Brandau R, Lippold BH, editors. Dermal and transdermal absorption, Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH. pp 154-170.
3. Mazer NA, Heiber WE, Moellmer JF, Meikle WA, Stringham JD, Sanders SW, Tollman KG, Odell WD. 1992. Enhanced transdermal delivery of testosterone: A new physiological approach for androgen replacement in hypogonadal men. J Control Release 19:347-362.
4. Higuchi T, Hussain A. 1979. Device consisting of copolymer having acetoxy groups for delivery of drugs. US Patent 4,144,317.
5. Campell PS, Eckenhoff JB. 1987. Transdermal therapeutic system having improved delivery characteristic. US Patent 4,704,282.
6. Meikle AW. 1998. A permeation-enhanced nonscrotal testosterone transdermal system for the treatment of male hypogonadism. In: Nieschlag E, Behre HM, editors. Testosterone-action, deficiency, substitution, 2nd edition Berlin: Springer-Verlag, pp 389-422.
7. Schaison G, Couzinet B, Behre HM. 1998. Percutaneous dihydrotestosterone treatment. In: Nieschlag E, editor. Testosterone-action, deficiency, substitution, 2nd edition Berlin: Springer-Verlag, pp 329-348.
8. Laufen H, Leitold M. 1992. Biodisponibility and metabolism of isosorbide dinitrate from a transdermal spray. Arzneim Forsch 42:931-935.
9. Morgan TM, Parr RA, Reed BL, Finnin BC. 1998. Enhanced transdermal delivery of sex hormones in swine with a novel topical aerosol. J Pharm Sci 87:1219-1225.
10. Morgan TM, Reed BL, Finnin BC. 1998. Enhanced skin permeation of sex hormones with novel topical spray vehicles. J Pharm Sci 87:1213-1218.
11. Monash University. Dermal penetration enhancers and drug delivery systems involving same. Australia. Patent WO 97/29735.
12. Huisman R, Van Kamp HV, Weyland JW, Doornbos DA, Bolhuis GK, Lerk CF. 1984. Development and optimization of pharmaceutical formulations using a simplex lattice design. Pharm Weekbl Sci 6:185-194.
13. Leichtnam ML, Rolland H, Wüthrich P. 2003. New aerosol transdermal drug delivery system-Effects of formulation parameters upon spray characteristics and permeation enhancement. Proc APGI, Symp Skin Formulation #43.
14. Leichtnam ML, Rolland H, Wüthrich P, Guy RH. 2005. Identification of penetration enhancers for testosterone transdermal delivery from spray formulations. J Controlled Release (in press).
15. Kim MK, Lee CH, Kim DD. 2000. Skin permeation of testosterone and its ester derivatives. J Pharm Pharmacol 52:369-375.
16. Hatanaka T, Shimoyama M, Sugibayashi K, Morimoto Y. 1993. Effect of vehicle on the skin permeability of drugs:polyethylene glycol 400-water and ethanol-water binary solvents. J Control Release 23:247-260.
17. Berner B, Mazzenga GC, Otte JH, Steffens RJ, Juang R-H, Ebert CD. 1989. Ethanol:water mutually enhanced transdermal therapeutic system:II. Skin permeation of ethanol and nitroglycerin, J Pharm Sci 78:402-407.
18. Williams AC, Barry BW. 2004. Penetration enhancers. Adv Drug Del Rev 56:603-618.
19. Davis J, Hadgraft J. 1993. Supersaturated solutions as topical drug delivery systems. In: Walters K, Hadgraft J, editors. Pharmaceutical skin permeation enhancement, New York: Marcel Dekker. pp 243-267.
20. Higuchi T. 1960. Physical chemical analysis of percutaneous absorption process. J Soc Cosmetic Chemists 11:85-97.
21. Ostrenga J, Steinmetz C, Poulsen B. 1971. Significance of vehicle composition. I: relationship between topical vehicle composition, skin penetrability, and clinical efficacy. J Pharm Sci 60:1175-1179.
22. Ostrenga J, Steinmetz C, Poulsen B, Yett S. 1971. Significance of vehicle composition. II: prediction of optimal vehicle composition. J Pharm Sci 60:1180-1183.
23. Woodford R, Barry BW. 1982. Optimisation of bioavailability of topical steroids: Thermodynamic control. J Invest Dermatol 79:388-391.
24. Barry BW. 1983. Properties that influence percutaneous absorption. In: Barry BW, editor. Dermatological formulations, New York: Marcel Dekker. pp. 127-233.
25. Holegaard A, Møllgaard B. 1985. Dermal drug delivery-improvement by choice of vehicle or drug derivative. J Control Release 2:111-120.
26. Panchagnula R, Salve PS, Thomas NS, Jain AK, Ramarao P. 2001. Transdermal delivery of naloxone: Effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin. Int J Pharm 219:95-105.
27. Wilkins NF, Klose K, Morgan TM, Reed BL, Finnin BC. 2004. Metastable pharmaceutical compositions. Patent WO200400361.
28. Rowe R, Sheskey P, Weller P, editors. 1995. CD-Rom handbook of pharmaceutical excipients, 4th edition. London, UK: Science and Practice, Royal Pharmaceutical Society of Great Britain.
29. Fang J-Y, Kuo C-T, Huang Y-B, Wu P-C, Tsai Y-H. 1999. Transdermal delivery of sodium nonivamide acetate from volatile vehicles: Effects of polymers. Int J Pharm 176:156-167.
30. Sekkat N, Guy RH. 2001. Biological models to study skin permeation. In: Testa B, van der Waterbeemd H, Folkers G, Guy RH, editors. Pharmacokinetic optimization in drug research: Biological, physicochemical and computational strategies, Lausanne: Wiley-VCH. pp 155-172.